Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by SizzlinSteakson Dec 09, 2017 9:05pm
104 Views
Post# 27125188

RE:RE:RE:Kalytera Therapeutics - Four Critical Points

RE:RE:RE:Kalytera Therapeutics - Four Critical PointsYou are absolutely right. This article is written with a complete negative bias. They failed to metion any positives such as average valuations for phase 2 trials being in the ballpark of $1 billion. They failed to make comparisons to other cannabis stocks which would clearly illustrate how undervalued it currently is and as you mentioned the previously announced PP is likely to close soon and put $5 million in the bank.  Any common sense writer would have balance to their article and outline positives along with potential negatives. It is clear that this article was written with a specific agenda.

DC01234 wrote:

wow i have heard of paid bashers, but this article takes the cake. how many shares short are you on this stock. you better take your profits and run, because KALY has been at the top of the volume charts for a week straight. there is nothing you can say to stop that. it stayed there on legitimate hard fact good news.

from the third paragraph, this says it all "In order to quell this hype, we elected to outline a few details related to Kalytera. Our hope is that investors begin to act rationally around the stock (and others, but that’s a battle for another day)."

if you think the people need to settle down and it's your job to "quell this hype", then you are not a hero sent to save people from a bad investment. your the guy shorting the hell out of a good stock, and trying to scare new and small time investors into selling their shares to you for cheap. weather your short or acummulating, your article is absolute garbage and nonsenese mixed with just enough small facts to make it sound believable. i'm talking about the possible dilution, which happens to all stocks at one point or another.

you want to talk about revenues. tesla, amazon and wal-mart all bleed money. people invest in ideas they believe will be profitable and benefit everyone, mostly themselves though. the stock market isn't near as much math and charts as it is people and their behavior. if you think that your prediction that people are overhyped on this is correct, then you are way off the mark here. this is the KALY comeback and they set up the dominos just right so far for the near future. after the volume of late I don't see why they wouldn't have finished their recent placement for $5,000,000 easily.

thats just my opinion on this though.



Bullboard Posts